title: The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
authors.affiliation: Department of Hematology/Oncology L and A Seràgnoli, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy. francesca.palandri@libero.it
authors.forename: Francesca
authors.initials: F
authors.lastname: Palandri
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Ilaria
authors.initials: I
authors.lastname: Iacobucci
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Marilina
authors.initials: M
authors.lastname: Amabile
authors.forename: Gabriele
authors.initials: G
authors.lastname: Gugliotta
authors.forename: Angela
authors.initials: A
authors.lastname: Poerio
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Testoni
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
authors.forename: Monica
authors.initials: M
authors.lastname: Crugnola
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rege-Cambrin
authors.forename: Bruno
authors.initials: B
authors.lastname: Martino
authors.forename: Ivana
authors.initials: I
authors.lastname: Pierri
authors.forename: Franca
authors.initials: F
authors.lastname: Radaelli
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D053208:Kaplan-Meier Estimate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl